CureVac - Hauptforum Forum: Community User: NeulingImDAX

@Jonathan7 Bitte Quellen immer angeben. Auch wenn diese nicht in deutsch sind. Erhöht einfach die Glaubwürdigkeit. Und bei Ihrer sehr engagierten Tätigkeit ausschliesslich im Curevac-Forum, kann dies nicht schaden ;-)

Misterx19000. Yes apologies- I dont like placing links -when they dont translate to German, please accept my apologies https://www.todojujuy.com/pais/la-vacuna-curevac-mostro-una-eficacia-del-95-n204721

@ QVC !!! Du hast dich verirrt! Die Aufnahme ist in Düsseldorf

Regarding the symptoms of the vaccine, the director explained that "there were some minor manifestations such as low-grade fever, muscle aches, the usual of a vaccine." In addition, he highlighted that severe allergic reactions were not recorded either. "The study had opened the registration for 9 thousand volunteers in different parts of the Province, a center in Rosario and another in CABA. Among them, some received both doses of the vaccine to be tested, while others were inoculated with a placebo. In addition, not only the German company is carrying out the studies in Berazategui, but they are also working in two public hospitals in the province of Buenos Aires: the Vicente López y Planes de General Rodríguez Hospital, and the Ramón Carrillo de Tres de Febrero.

Jonathan7 today 12:38 pm 0 Studies of the German vaccine, Curevac, in Argentina, showed an efficacy of 95% where the research headquarters is located in Berazategui and it is expected to be approved this month. The results of the formula used by the biopharmaceutical company confirmed the 95% efficacy of the vaccine against the SARS-CoV-2 virus, 28 days after the first dose and seven days after the second. They report that the Curevac vaccine appears to be "very well positioned" and was developed with the support of the German government and the European Community, and successfully completed phase 1 and phase 2 trials. Now the vaccine is in phase 3 in different countries around the world. For example, in Argentina, the Buenos Aires Ministry of Health opened registration to participate in clinical trials on March 18, under the general coordination of the Evita Pueblo hospital in Berazategui. Juan Marini, executive director of the hospital, indicated that “the protocol has a 13-month follow-up, although it may continue until two years. We assume that in the first days of June the study will be approved in Europe. From there, it will be easy for the ANMAT to approve it ”.

Jonathan, könntest du mal unter deinen Beiträgen eine Quelle angeben?

Regarding the symptoms of the vaccine, the director explained that "there were some minor manifestations such as low-grade fever, muscle aches, the usual of a vaccine." In addition, he highlighted that severe allergic reactions were not recorded either. " The study had opened the registration for 9 thousand volunteers in different parts of the Province, a center in Rosario and another in CABA. Among them, some received both doses of the vaccine to be tested, while others were inoculated with a placebo. In addition, not only the German company is carrying out the studies in Berazategui, but they are also working in two public hospitals in the province of Buenos Aires: the Vicente López y Planes de General Rodríguez Hospital, and the Ramón Carrillo de Tres de Febrero .

Studies of the German vaccine , Curevac , in Argentina, showed an efficacy of 95% where the research headquarters is located in Berazategui and it is expected to be approved this month. The results of the formula used by the biopharmaceutical company confirmed the 95% efficacy of the vaccine against the SARS-CoV-2 virus, 28 days after the first dose and seven days after the second. They report that the Curevac vaccine appears to be "very well positioned" and was developed with the support of the German government and the European Community, and successfully completed phase 1 and phase 2 trials. Now the vaccine is in phase 3 in different countries around the world. For example, in Argentina, the Buenos Aires Ministry of Health opened registration to participate in clinical trials on March 18, under the general coordination of the Evita Pueblo hospital in Berazategui. Juan Marini, executive director of the hospital, indicated that “the protocol has a 13-month follow-up, although it may continue until two years. We assume that in the first days of June the study will be approved in Europe. From there, it will be easy for the ANMAT to approve it ”.

@Newe : interessant 🧐

@BreitF habe das gelesen! Ja - sehr interessant - von der medizinischen Kompetenz des Schreiberlings bin ich beeindruckt

ANMAT have asked for the vaccine- it showed 95% in effficacy in 3 trials Argentina- I am not saying that is right or wrong but on June 4 ANMAT requested Curevac supply to them its published as well

@M610 die Kommunikation von gestern ! Hatte die Frage aufgeworfen, wie es mit der Erstellung vontheoretischen Nachweisen aussieht beDonald 23:18 von Ruudi ::: Das ist offenbar tatsächlich der Fall. Ich hatte vor rd. 2. Wochen einmal auf das Design der von der UK Gesundheitsbehörde PHE bezahlten Studie aufmerksam gemacht. Danach wurden die Zahlen der in UK massgeblich verimpften Vakzine (AZ und BioNTech) mittels mathematischer Verfahren geschätzt. Dies wurde von zahlreichen britischen Experten heftig kritisiert. Der entsprechende Link bei PHE wurde offenbar entfernt. Aber ich glaube das hier ist die Studie (Auftraggeber S.1; Design ab S.4 ff.). https://khub.net/documents/135939561/405676950/Increased Household Transmission of COVID-19 Cases - national case study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa Vgl. dazu auch die Einschätzung der renommierten und anerkannten Fachpublikation The Lancet: https://www.aerzteblatt.de/nachrichten/124417/Grossbritannien-Delta-Variante-von-SARS-CoV-2-breitet-sich-bei-offenbar-verminderter-Impfstoffwirkung-weiter-aus bzw. direkt https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext Dazu passt der folgende Spruch, der gerüchteweise Winston Churchill zugeschrieben wird: „Ich glaube nur der Statistik, die ich selbst gefälscht habe …“